400 Phase I study of JI-101, a novel oral tyrosine kinase inhibitor that selectively targets EphB4, VEGFR2, and PDGFRβ
| Autor: | L. Miller, Michael S. Gordon, R. Mullangi, Mark Velleca, M. Sahu, Sunil Sharma, D. Brittelli, R. Govindarajan, Nuggehally R. Srinivas |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Cancer Research
biology MAP kinase kinase kinase Chemistry Mitogen-activated protein kinase kinase Molecular biology Tropomyosin receptor kinase C Receptor tyrosine kinase Oncology biology.protein Bruton's tyrosine kinase Cyclin-dependent kinase 9 Janus kinase Proto-oncogene tyrosine-protein kinase Src |
| Zdroj: | European Journal of Cancer Supplements. 8:127 |
| ISSN: | 1359-6349 |
| DOI: | 10.1016/s1359-6349(10)72107-8 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect